MYD88 and diffuse large B-cell lymphoma: Furthermore, because CUDC-907 down-regulated the expression of MyD88 transcripts and protein, irrespective of its mutation status, future studies could focus on investigating a potential role for CUDC-907 in overcoming resistance to ibrutinib in DLBCL carrying MyD88 mutations.